Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
Recent Articles
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
- CHINA BULLETIN: Services, Trade Send Positive Signals
- Lopal Tech seeks cash after losses balloon with lithium price plunge
-
Goldwind’s profit tumbles as China sales start to deflate
2208.HK 002202.SHE
